OncoMatch/Clinical Trials/NCT07181941
Response-Based Dose Reduction of Linvoseltamab in the Treatment of Relapsed, Refractory, or Triple-Class Relapsed/Refractory Multiple Myeloma
Is NCT07181941 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies Linvoseltamab for recurrent multiple myeloma.
Treatment: Linvoseltamab — This phase I/II trial evaluates the safety and feasibility of early, response-based dose reduction of linvoseltamab in the treatment of patients multiple myeloma that has come back after a period of improvement (relapsed), that does not respond to treatment (refractory), or that is resistant to three classes of therapeutic agents, including proteasome inhibitors, immunomodulatory agents, and monoclonal antibodies (triple-class relapsed/refractory). Linvoseltamab is a bispecific antibody. Upon administration, linvoseltamab binds to the BCMA protein on cancer cells and the CD3 protein on T cells (a type of immune cell). This generates an immune response that stimulates the T cells to kill the cancer cells. Optimal dosing schedules of linvoseltamab have not yet been determined. Reducing the dosage of linvoseltamab may reduce treatment-related side effects while maintaining long-term disease outcomes.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Cancer type
Multiple Myeloma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: proteasome inhibitor
received at least 4 prior lines of therapy including proteasome inhibitor (PI), immunomodulatory imide drug (IMiD), and anti-CD38 monoclonal antibody
Must have received: immunomodulatory imide drug
received at least 4 prior lines of therapy including proteasome inhibitor (PI), immunomodulatory imide drug (IMiD), and anti-CD38 monoclonal antibody
Must have received: anti-CD38 monoclonal antibody
received at least 4 prior lines of therapy including proteasome inhibitor (PI), immunomodulatory imide drug (IMiD), and anti-CD38 monoclonal antibody
Cannot have received: CAR-T cell therapy
Previous treatment with chimeric antigen receptor (CAR) T therapy or any gene therapy products
Cannot have received: gene therapy
Previous treatment with chimeric antigen receptor (CAR) T therapy or any gene therapy products
Lab requirements
Blood counts
Platelet count ≥50 x 10⁹/L (no transfusion ≤7 days); ANC ≥1.0 x 10⁹/L (no G-CSF ≤2 days); Hemoglobin ≥8.0 g/dL
Kidney function
Serum creatinine clearance by Cockcroft-Gault ≥30 mL/min (measured CrCl ≥30 mL/min allowed at PI discretion)
Liver function
Total bilirubin ≤1.5 x ULN (Gilbert syndrome exception); ALT/AST ≤2.5 x ULN; alkaline phosphatase ≤2.5 x ULN
Adequate organ function (based on testing ≤14 days prior to registration): ... see details
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Fred Hutch/University of Washington Cancer Consortium · Seattle, Washington
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07181941 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior CAR-T cell therapy, gene therapy disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages